The effects of clinical trials on improving breast cancer care at a single institution

Autor:	W. C. Dooley, J. Parker, J. Bong
Rok vydání:	2011
Předmět:	Surgical oncologist Cancer Research medicine.medical_specialty Chemotherapy business.industry General surgery medicine.medical_treatment medicine.disease Clinical trial Radiation therapy Breast cancer Oncology Surgical oncology medicine Physical therapy Hormonal therapy Single institution business
Zdroj:	Journal of Clinical Oncology. 29:198-198
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2011.29.27_suppl.198
Popis:	198 Background: We reported in 2011 at the Society of Surgical Oncology a 19 year retrospective at a single academic institution which identified practice differences between surgical oncologists and general surgeons which were associated with a significant survival advantage. Clinical trial participation was much higher amongst patients treated by a surgical oncologist. Methods: This is an IRB approved, retrospective review of all breast cancer patients receiving primary treatment at a single institution from 1/1/2001 to 12/31/2008. Details of pathology, surgical therapy, chemotherapy, hormonal therapy and radiation therapy were compared between patients participating in clinical trials and those not participating. The specific trials were segregated as to type (tissue banking, therapeutic, prevention, etc.) to understand differential effects if any between type of trial participation. Results: During the time period, there were 1220 patients who received primary breast cancer treatment at this institution. The mean age was 55.6 and mean follow-up >40 months. Stage distribution was stage 0 - 16.8%, Stage 1 - 26.6%, Stage 2 - 33.1%, Stage 3 - 15.9%, and Stage 4 - 6.1%. Patients participating in any clinical trial numbered 468 and 752 participated in no clinical trials. Overall survival (clinical trial 98.8% vs. not in clinical trial 75.7%; p Conclusions: High volume clinical trial enrollment is associated with the best overall treatment outcomes in breast cancer whether trials are directly related to therapeutic changes or not. Each individual in the breast center treating team can have dramatic effect on outcomes by improving their clinical trial enrollment and participation.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::8c59d39fbdbcba3612101d4b99ef4730 https://doi.org/10.1200/jco.2011.29.27_suppl.198 Zobrazit plný text záznamu